Remission of severe myasthenia gravis after autologous stem cell transplantation.
Monica I SchlatterSoumya S YandamuriKevin C O'ConnorRichard J NowakMinh C PhamAbeer H ObaidCallee RedmanMarie ProvostPeter A McSweeneyMichael L PearlmanMichael T TeesJames D BowenRichard A NashGeorge E GeorgesPublished in: Annals of clinical and translational neurology (2023)
HDIT/HCT induced a complete response of disease activity in a patient with severe refractory MG. This response may suggest that a cell-mediated etiology may be a significant contributing factor in refractory MG cases. A phase 2 clinical trial is warranted to establish if HDIT/HCT can be an effective therapy for severe refractory MG and to gain a further understanding of disease pathogenesis.
Keyphrases
- disease activity
- stem cell transplantation
- rheumatoid arthritis
- systemic lupus erythematosus
- clinical trial
- early onset
- myasthenia gravis
- high dose
- rheumatoid arthritis patients
- drug induced
- cell therapy
- juvenile idiopathic arthritis
- single cell
- bone marrow
- high glucose
- open label
- cell cycle arrest
- randomized controlled trial
- oxidative stress
- diabetic rats
- mesenchymal stem cells
- double blind